2337. National Bronchiolitis Hospitalization Rates Among Preterm and Full Term Infants: 2010–2015
Session: Poster Abstract Session: Pediatric Virology
Saturday, October 7, 2017
Room: Poster Hall CD
  • Krilov_IDWeek 2017_Final_03Oct2017.pdf (337.2 kB)
  • Background: The 2014 American Academy of Pediatrics (AAP) policy statement on respiratory syncytial virus immunoprophylaxis (RSV IP) recommended against its use in infants 29–34 weeks gestational age (wGA) without chronic lung disease or bronchopulmonary dysplasia (CLD/BPD) or congenital heart disease (CHD). This study examined the impact of these changes by evaluating RSV IP use and bronchiolitis hospitalization rates among full-term (FT) and preterm (PT) infants 29–34 wGA in the 2014–15 RSV season relative to previous seasons.

    Methods: Infants born 7/1/2009 to 6/30/2015 were identified in the MarketScan Multistate Medicaid (MED) and Commercial (COM) databases; DRG and ICD-9-CM codes were used to select FT and PT infants without CLD/BPD or CHD. Outpatient RSV IP use was identified by drug and administration codes. Bronchiolitis hospitalizations were identified by diagnosis codes (466.11 and 466.19) during the RSV season (Nov–Mar) and summarized by chronologic age (CA). Hospitalization rates were calculated per 100 infant-seasons, and statistical significance was tested using generalized linear regression models with Poisson error, log link, and log offset for exposure time.

    Results: 1.1 mil MED and 1.0 mil COM births were identified; 5.2% MED and 4.8% COM infants were born at 29–34 wGA. RSV IP use decreased among MED and COM infants 29–34 wGA (P<.01) in 2014–15 compared to 2013–14. Bronchiolitis hospitalization rates increased for MED and COM infants 29–34 wGA in 2014–15 compared to 2013–14 (rate ratios <3 months CA: MED 1.45, P=.009 and COM 2.1, P=.004; 3–6 months CA: MED 1.35, P=.023 and COM 1.7, P=.053), whereas the rates for FT infants remained the same (rate ratios 0.94–1.08, P>.05). Absolute increases were greatest for infants 29–30 wGA and <3 months CA (MED +10.0 and COM +8.3 per 100 infant-seasons). Similar trends were observed when 2014–15 was compared to the combined 2010–14 RSV seasons.

    Conclusion: In the 2014–15 RSV season, there was an increase in bronchiolitis hospitalization rates among PT infants born at 29–34 wGA when <3 months and 3–6 months CA, but no increase among FT infants. Trends were consistent in the MED and COM populations and are associated with the change to AAP policy.

    Funding: AstraZeneca

    Leonard R. Krilov, MD1, Jaime Fergie, MD2, Mitchell Goldstein, MD3, Kimmie K. McLaurin, MS4, Sally Wade, MPH5, David Diakun, BS6 and Amanda Kong, MPH6, (1)Children’s Medical Center, NYU Winthrop, Mineola, NY, (2)Driscoll Children's Hospital, Corpus Christi, TX, (3)Loma Linda University Children’s Hospital, Loma Linda, CA, (4)Department of Health Economics and Outcomes Research, AstraZeneca, Gaithersburg, MD, (5)Wade Outcomes Research and Consulting, Salt Lake City, UT, (6)Truven Health Analytics, an IBM Company, Cambridge, MA


    L. R. Krilov, AstraZeneca/MedImmune: Consultant , Research grant and Research support

    J. Fergie, MedImmune: Speaker's Bureau , Research grant and Research support

    M. Goldstein, AstraZeneca/MedImmune: Consultant , Research grant and Research support

    K. K. McLaurin, AstraZeneca: Employee , Salary

    S. Wade, Truven Health Analytics: Consultant , Consulting fee

    D. Diakun, Truven Health Analytics: Employee , Salary

    A. Kong, Truven Health Analytics: Employee , Salary

    See more of: Pediatric Virology
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.